Prof. Dr. med. Christoph Kleinschnitz - Neurologie, Essen - Publikationen

Impact Faktoren (IF) 2015 in Klammern

Kumulativer Impact Faktor: 924,7
Kumulative Zitierungen: 5956
Zitierungen in 2015: 1087
h-Index: 45
*Abfrage Google Scholar/Web of Science am 03.08.2016

1. Originalarbeiten
a. Erst-/Seniorautor

1. Kleinschnitz C, Mencl S, Kleikers PW, Schuhmann MK, G López M, Casas AI, Sürün B, Reif A, Schmidt HH (2016). NOS knockout or inhibition but not disrupting PSD-95-NOS interaction protect against ischemic brain damage. J Cereb Blood Flow Metab (im Druck) (IF 4.9)

2. Hopp, S, Albert-Weissenberger, C, Mencl, S, Bieber, M, Schuhmann, MK, Stetter, C, Nieswandt, B, Schmidt, PM, Monoranu, CM, Alafuzoff, I, Marklund, N, Nolte, MW, Siren, AL, Kleinschnitz, C (2016). Targeting coagulation factor XII as a novel therapeutic option in brain trauma. Ann Neurol 79, 970-982 (IF 9,6)

3. Dittmeier M, Kraft P, Schuhmann MK, Fluri F, Kleinschnitz C (2015) Pretreatment with rivaroxaban attenuates stroke severity in rats by a dual antithrombotic and anti-inflammatory mechanism. Thrombosis and Haemostasis 115: 835-43 (IF 5,3)

4. Kraft P, Schuhmann MK, Fluri F, Lorenz K, Zernecke A, Stoll G, Nieswandt B, Kleinschnitz C (2015) Efficacy and safety of platelet glycoprotein receptor blockade in aged and comorbid mice with acute experimental stroke. Stroke, 46:3502-6 (IF 5,8)

5. Kraft P, Drechsler C, Schuhmann MK, Gunreben I, Kleinschnitz C (2015) Characterization of peripheral immune cell subsets in patients with acute and chronic cerebrovascular disease: a case–control study. Int J Mol Sci, 16:25433-49 (IF 2,8)

6. Fluri F, Bieber M, Volkmann J, Kleinschnitz C (2015) Microelectrode guided implantation of electrodes into the subthalamic nucleus of rats for long-term deep brain stimulation. J Vis Exp, doi: 10.3791/53066. (IF 1,1)

7. Kleikers P, Hooijmans C, Göb E, Langhauser F, Rewell S, Radermacher K, Ritskes-Hoitinga M, Howells D, Kleinschnitz C*, Schmidt H* (2015) Combining pre-clinical meta-analysis and a randomized confirmatory trial approach for therapeutic target validation: the case of NOX2 in stroke. Sci Rep 5:13428 (*gemeinsamer Seniorautor) (IF 5,2)

8. Kleinschnitz C, Niemczyk G, Rehberg-Weber K, Wernsdörfer C (2015) Interferon Beta-1a (AVONEX®) as a Treatment Option for Untreated Patients with Multiple Sclerosis (AXIOM): A Prospective, Observational Study. Int J Mol Sci 16:15271-86 (IF 3,3)

9. Göb E, Reymann S, Langhauser F, Schuhmann MK, Kraft P, Thielmann I, Göbel K, Brede M, Homola G, Solymosi L, Stoll G, Geis C, Meuth SG, Nieswandt B, Kleinschnitz C (2015) Blocking of plasma kallikrein ameliorates stroke by reducing thromboinflammation. Ann Neurol 77:784-803 (IF 9,6)

10. Schuhmann MK, Kraft P, Stoll G, Lorenz K, Meuth SG, Wiendl H, Nieswandt B, Sparwasser T, Beyersdorf N, Kerkau T, Kleinschnitz C (2015) CD28 superagonist-mediated boost of regulatory T cells increases thrombo-inflammation and ischemic neurodegeneration during the acute phase of experimental stroke. J Cereb Blood Flow Metab 35:6-10 (IF 4,9)

11. Kraft P, Drechsler C, Gunreben I, Heuschmann PU, Kleinschnitz C (2015) Case-Control Study of Platelet Glycoprotein Receptor Ib and IIb/IIIa Expression in Patients with Acute and Chronic Cerebrovascular Disease. PLoS One 10:e0119810 (IF 3,1)

12. Göb E, Bittner S, Bobak N, Kraft P, Göbel K, Langhauser F, Homola GA, Brede M, Budde T, Meuth SG, Kleinschnitz C (2014) The two-pore domain potassium channel KCNK5 deteriorates outcome in ischemic neurodegeneration. Pflugers Arch 467:973-87 (IF 3,7)

13. Albert-Weissenberger C, Mencl S, Schuhmann MK, Salur I, Göb E, Langhauser F, Hopp S, Hennig N, Meuth SG, Nolte MW, Sirén AL, Kleinschnitz C (2014) C1-Inhibitor protects from focal brain trauma in a cortical cryolesion mice model by reducing thrombo-inflammation. Front Cell Neurosci 8:269 (IF 4,6)

14. Kraft P, Drechsler C, Gunreben I, Heuschmann PU, Kleinschnitz C (2014) Regulation of blood coagulation factors XI and XII in patients with acute and chronic cerebrovascular disease: a case-control study. Cerebrovasc Dis 38:337-43 (IF 3,7)

15. Mencl S, Hennig N, HoppS, Schuhmann MK, Albert-Weißenberger C, Sirén AL, Kleinschnitz C (2014) FTY720 does not protect from traumatic brain injury in mice despite reducing posttraumatic inflammation. J Neuroimmunol 274:125-31 (IF 2,5)

16. Langhauser F, Kraft P, Göb E, Leinweber J, Schuhmann MK, Lorenz K, Gelderblom M, Bittner S, Meuth SG, Wiendl H, Magnus T, Kleinschnitz C (2014) Blocking of α4 Integrin Does Not Protect From Acute Ischemic Stroke in Mice. Stroke, 45:1799-06 (IF 5,8)

17. Kraft P, Drechsler C, Gunreben I, Nieswandt B, Stoll G, Heuschmann PU, Kleinschnitz C (2014) von Willebrand factor regulation in patients with acute and chronic cerebrovascular disease: a pilot, case–control study. PLoS One 9:e99851 (IF 3,1)

18. Kraft P, Göbel K, Meuth SG, Kleinschnitz C (2014) Glatiramer acetate does not protect from acute ischemic stroke in mice. Exp Transl Stroke Med 6:4 (kein IF)

19. Kraft P, Göb E, Schuhmann MK, Göbel K, Deppermann C, Thielmann I, Herrmann AM, Lorenz K, Brede M, Stoll G, Meuth SG, Nieswandt B, Pfeilschifter W, Kleinschnitz C (2013) FTY720 ameliorates acute ischemic stroke in mice by reducing thrombo-inflammation but not by direct neuroprotection. Stroke 44:3202-10 (IF 5,8)

20. Kraft P, Schwarz T, Göb E, Heydenreich N, Brede M, Meuth SG, Kleinschnitz C (2013) The phosphodiesterase-4 inhibitor rolipram protects from ischemic stroke in mice by reducing blood-brain-barrier damage, inflammation and thrombosis. Exp Neurol 247C:80-90 (IF 4,7)

21.Kleinschnitz C*, Kraft P, Dreykluft A, Hagedorn I, Göbel K, Schuhmann MK, Langhauser F, Helluy X, Schwarz T, Bittner S, Mayer CT, Brede M, Varallyay C, Pham M, Bendszus M, Jakob P, Magnus T, Meuth SG, Iwakura Y, Zernecke A, Sparwasser T, Nieswandt B, Stoll G, Wiendl H (2013) Regulatory T cells are strong promoters of acute ischemic stroke in mice by inducing dysfunction of the cerebral microvasculature. Blood 120:679-91 (*korrespondierender Autor) (IF 11,8)

22. Langhauser F, Göb E, Kraft P, Geis C, Schmitt J, Brede M, Göbel K, Helluy X, Pham M, Bendszus M, Jakob P, Stoll G, Meuth SG, Nieswandt B, McKrae KR, Kleinschnitz C (2012) Kininogen deficiency protects from ischemic neurodegeneration in mice by reducing thrombosis, blood-brain-barrier damage and inflammation. Blood 120:4082-92 (IF 11,8)

23. Heydenreich N, Nolte MW, Göb E, Langhauser F, Hofmeister M, Kraft P, Albert-Weissenberger C, Brede M, Varallyay C, Göbel K, Meuth SG, Nieswandt B, Dickneite G, Stoll G, Kleinschnitz C (2012) C1-Inhibitor protects from brain ischemia-reperfusion injury by combined anti-inflammatory and anti-thrombotic mechanisms. Stroke 43:2457-67 (IF 5,8)

24. Albert-Weissenberger C, Stetter C, Meuth SG, Göbel K, Bader M, Sirén AL, Kleinschnitz C (2012) Blocking of bradykinin receptor B1 protects from focal closed head injury in mice by reducing axonal damage and astroglia activation. J Cereb Blood Flow Metab 32:1747-56 (IF 4,9)

25. Brede M, Braeuninger S, Langhauser F, Hein L, Roewer N, Stoll G, Kleinschnitz C (2011) Alpha2-adrenoceptors do not mediate neuroprotection in acute ischemic stroke in mice. J Cereb Blood Flow Metab 31:e1-7 (IF 4,9)

26. Pham M*, Helluy X*, Kleinschnitz C*, Kraft P, Bartsch AJ, Jakob P, Nieswandt B, Bendszus M, Stoll G (2011) Sustained reperfusion after blockade of glycoprotein-receptor-Ib in focal cerebral ischemia: an MRI study at 17.6 Tesla. PLoS One 6:e18386 (*gemeinsamer Erstautor) (IF 3,1)

27. Kleinschnitz C*, Blecharz K, Kahles T, Schwarz T, Kraft P, Goebel K, Meuth SG, Burek M, Thum T, Stoll G, Förster CY (2011) Glucocorticoid insensitivity at the hypoxic blood-brain-barrier can be reversed by inhibition of the proteasome. Stroke 42:1081-9 (*korrespondierender Autor) (IF 5,8)

28. Goebel K, Pankratz S, Schneider-Hohendorf T, Bittner S, Schuhmann MK, Langer HF, Stoll G, Wiendl H, Kleinschnitz C*, Meuth SG* (2011) Blockade of the kinin receptor B1 protects from autoimmune CNS disease by reducing leukocyte trafficking. J Autoimmun 36:106-14 (*gemeinsamer Seniorautor) (IF 7,8)

29. Kleinschnitz C*, Grund H, Wingler K, Armitage ME, Jones E, Mittal M, Barit D, Schwarz T, Geis C, Kraft P, Barthel K, Schumann MK, Herrmann AM, Meuth SG, Stoll G, Meurer S, Becker L, Gailus-Durner V, Fuchs H, Klopstock T, Hrabé de Angelis M, Jandeleit-Dahm K, Shah AM, Weissmann N, Schmidt HHHW (2010) Post-stroke inhibition of induced NADPH oxidase type 4 prevents oxidative stress and neurodegeneration. PLoS Biol 8:e1000479 (*korrespondierender Autor) (IF 8,7)

30. De Meyer SF, Schwarz T, Deckmyn H, Denis CV, Nieswandt B, Stoll G, Vanhoorelbeke K, Kleinschnitz C (2010) Binding of von Willebrand Factor to Collagen and Glycoprotein Ib{alpha}, But Not to Glycoprotein IIb/IIIa, Contributes to Ischemic Stroke in Mice. Arterioscler Thromb Vasc Biol 30:1949-51 (IF 6,0)

31. Kleinschnitz C*, Schwab N, Kraft P, Hagedorn I, Dreykluft A, Schwarz T, Austinat M, Nieswandt B, Wiendl H, Stoll G (2010) Early detrimental T-cell effects in experimental cerebral ischemia are neither related to adaptive immunity nor thrombus formation. Blood 115:3835-42 (*korrespondierender Autor) (IF 11,8)

32. Kraft P, Schwarz T, Meijers JC, Stoll G, Kleinschnitz C (2010) Thrombin-activatable fibrinolysis inhibitor (TAFI) deficient mice are susceptible to intracerebral thrombosis and ischemic stroke. PLoS One 5:e11658 (IF 3,1)

33. Kraft P, Schwarz T, Pochet L, Stoll G, Kleinschnitz C (2010) COU254, a specific 3-carboxamide-coumarin inhibitor of coagulation factor XII, does not protect mice from acute ischemic stroke. Exp Transl Stroke Med 2:5 (kein IF)

34. Kraft P, Benz PM, Austinat M, Brede ME, Schuh K, Walter U, Stoll G, Kleinschnitz C (2010) Deficiency of vasodilator-stimulated phosphoprotein (VASP) increases blood-brain-barrier damage and edema formation after ischemic stroke in mice. PLoS One 5:e15106. (IF 3,1)

35. Raslan F, Schwarz T, Meuth SG, Austinat M, Bader M, Renné T, Roosen K, Stoll G, Sirén AL, Kleinschnitz C (2010) Inhibition of bradykinin receptor B1 protects mice from focal brain injury by reducing blood-brain barrier leakage and inflammation. J Cereb Blood Flow Metab 30:1477-86 (IF 4,9)

36. Uçeyler N, Göbel K, Meuth SG, Ortler S, Stoll G, Sommer C, Wiendl H, Kleinschnitz C (2010) Deficiency of the negative immune regulator B7-H1 enhances inflammation and neuropathic pain after chronic constriction injury of mouse sciatic nerve. Exp Neurol 222:153-60 (IF 4,7)

37. Pham M*, Kleinschnitz C*, Helluy X, Bartsch AJ, Austinat M, Behr VC, Renné T, Nieswandt B, Stoll G, Bendszus M (2010) Enhanced cortical reperfusion protects coagulation factor XII-deficient mice from ischemic stroke as revealed by high-field MRI. Neuroimage 49:2907-14 (*gemeinsamer Erstautor) (IF 5,5)

38. Kleinschnitz C*, De Meyer SF, Schwarz T, Austinat M, Vanhoorelbeke K, Nieswandt B, Deckmyn H, Stoll G (2009) Deficiency of von Willebrand factor protects mice from ischemic stroke. Blood 113:3600-3 (*korrespondierender Autor) (IF 11,8)

39. Austinat M, Braeuninger S, Pesquero JB, Brede M, Bader M, Stoll G, Renné T, Kleinschnitz C (2009) Blockade of Bradykinin Receptor B1 but not Bradykinin Receptor B2 Provides Protection from Cerebral Infarction and Brain Edema. Stroke 40:285-93 (IF 5,8)

40. Stoll G*, Kleinschnitz C*, Meuth SG, Braeuninger S, Ip CW, Wessig C, Nölte I, Bendszus M (2009) Transient widespread blood-brain barrier alterations after cerebral photothrombosis as revealed by gadofluorine M-enhanced magnetic resonance imaging. J Cereb Blood Flow Metab 29:331-41 (*gemeinsamer Erstautor) (IF 4,9)

41. Meuth SG*, Kleinschnitz C*, Broicher T, Austinat M, Braeuninger S, Bittner S, Fischer S, Bayliss DA, Budde T, Stoll G, Wiendl H (2009) The neuroprotective impact of the leak potassium channel TASK1 on stroke development in mice. Neurobiol Dis 33:1-11 (*gemeinsamer Erstautor) (IF 4,8)

42. Kleinschnitz C, Braeuninger S, Pham M, Nölte I, Renné T, Nieswandt B, Bendszus M, Stoll G (2008) Blocking of Platelets or Intrinsic Coagulation Pathway Driven Thrombosis Does Not Prevent Cerebral Infarctions Induced by Photothrombosis. Stroke 39:1262-8 (IF 5,8)

43. Kleinschnitz C, Pozgajova M, Pham M, Bendszus M, Nieswandt B, Stoll G (2007) Targeting Platelets in Acute Experimental Stroke: Impact of GPIb, GPVI and GPIIb/IIIa Blockade on Infarct Size, Functional Outcome, and Intracranial Bleeding. Circulation 115:2323-30 (IF 17,1)

44. Kleinschnitz C, Stoll G, Bendszus M, Schuh K, Pauer U, Burfeind P, Renné C, Gailani D, Nieswandt B, Renné T (2006) Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis. J Exp Med 203:513-18 (IF 11,2)

45. Kleinschnitz C, Hofstetter HH, Meuth SG, Bräuninger S, Sommer C, Stoll G (2006) T-cell infiltration after chronic constriction injury of mouse sciatic nerve is associated with interleukin-17 expression. Exp Neurol 200:480-85 (IF 4,7)

46. Kleinschnitz C, Schutz A, Nolte I, Horn T, Frank M, Solymosi L, Stoll G, Bendszus M (2005) In vivo detection of developing vessel occlusion in photothrombotic ischemic brain lesions in the rat by iron particle enhanced MRI. J Cereb Blood Flow Metab 25:1548-55 (IF 4,9)

47. Kleinschnitz C, Brinkhoff J, Sommer C, Stoll G (2005) Contralateral cytokine gene induction after peripheral nerve lesions: Dependence on the mode of injury and NMDA receptor signalling. Brain Res Mol Brain Res 136:23-8 (IF 2,8)

48. Kleinschnitz C, Schroeter M, Jander, S, Stoll G (2004) Induction of granulocyte colony-stimulating factor mRNA by focal cerebral ischemia and cortical spreading depression. Brain Res Mol Brain Res 121:73-8 (IF 2,8)

49. Kleinschnitz C, Brinkhoff J, Zelenka M, Sommer C, Stoll G (2004) The extent of cytokine induction in peripheral nerve lesions depends on the mode of injury and NMDA receptor signaling. J Neuroimmunol 149:77-83 (IF 2,5)

50. Kleinschnitz C, Bendszus M, Frank M, Solymosi L, Toyka KV, Stoll G (2003) In vivo monitoring of macrophage infiltration in experimental ischemic brain lesions by magnetic resonance imaging. J Cereb Blood Flow Metab 23:1356-61 (IF 4,9)

b. Co-Autor

1. Münzer P, Walker-Allgaier B, Geue S, Geuss E, Hron G, Rath D, Eißler D, Winter S, Schaeffeler E, Meinert M, Schaller M, Greinacher A, Schwab M, Geisler T, Kleinschnitz C, Lang F, Gawaz M, Borst O (2016). PDK1 Determines Collagen-Dependent Platelet Ca2+ Signaling and Is Critical to Development of Ischemic Stroke In Vivo. Arterioscler Thromb Vasc Biol. 36:1507-16 (IF 6,0)

2. Rovituso DM, Scheffler L, Wunsch M, Kleinschnitz C, Dörck S, Ulzheimer J, Bayas A, Steinman L, Ergün S, Kuerten S (2016). CEACAM1 mediates B cell aggregation in central nervous system autoimmunity. Sci Rep 6:29847 (IF 5,2)

3. Schwab N, Schneider-Hohendorf T, Pignolet B, Spadaro M, Görlich D, Meinl I, Windhagen S, Tackenberg B, Breuer J, Cantó E, Kümpfel T, Hohlfeld R, Siffrin V, Luessi F, Posevitz-Fejfár A, Montalban X, Meuth SG, Zipp F, Gold R, Du Pasquier RA, Kleinschnitz C, Jacobi A, Comabella M, Bertolotto A, Brassat D, Wiendl H (2016). PML risk stratification using anti-JCV antibody index and L-selectin. Mult Scler 22:1048-60 (IF 4,2)

4. Israel I, Ohsiek A, Al-Momani E, Albert-Weissenberger C, Stetter, C, Mencl S, Buck AK, Kleinschnitz C, Samnick S and Siren AL (2016). Combined [(18)F]DPA-714 micro-positron emission tomography and autoradiography imaging of microglia activation after closed head injury in mice. J Neuroinflamm 13:140 (IF 4,7)

5.Göbel K, Pankratz S, Asaridou CM, Herrmann AM, Bittner S, Merker M, Ruck T, Glumm S, Langhauser F, Kraft P, Krug TF, Breuer J, Herold M, Gross CC, Beckmann D, Korb-Pap A, Schuhmann MK, Kuerten S, Mitroulis I, Ruppert C, Nolte MW, Panousis C, Klotz L, Kehrel B, Korn T, Langer HF, Pap T, Nieswandt B, Wiendl H, Chavakis,T, Kleinschnitz C, Meuth SG (2016). Blood coagulation factor XII drives adaptive immunity during neuroinflammation via CD87-mediated modulation of dendritic cells. Nat Commun 7:11626 (IF 11,3).

6. Denorme F, Langhauser F, Desender L, Vandenbulcke A, Rottensteiner H, Plaimauer B, Francois O, Andersson T, Deckmyn H, Scheiflinger F, Kleinschnitz C, Vanhoorelbeke K, De Meyer SF (2016). ADAMTS13-mediated thrombolysis of t-PA-resistant occlusions in ischemic stroke in mice. Blood 127: 2337-2345 (IF 11,8)

7. Purrucker, JC, Wolf, M, Haas, K, Rizos, T, Khan, S, Dziewas, R, Kleinschnitz, C, Binder, A, Groschel, K, Hennerici, MG, Lobotesis, K, Poli, S, Seidel, G, Neumann-Haefelin, T, Ringleb, PA, Heuschmann, PU and Veltkamp, R (2016). Safety of Endovascular Thrombectomy in Patients Receiving Non-Vitamin K Antagonist Oral Anticoagulants. Stroke 47:1127-1130 (IF 5,8)

8. Schuhmann MK, Gunreben I, Kleinschnitz C, Kraft P (2016). Immunohistochemical Analysis of Cerebral Thrombi Retrieved by Mechanical Thrombectomy from Patients with Acute Ischemic Stroke. Int J Mol Sci 17:298 (IF 3,3)

9. Schwarzmaier SM, de Chaumont C, Balbi M, Terpolilli NA, Kleinschnitz C, Gruber A, Plesnila N (2016). The Formation of Microthrombi in Parenchymal Microvessels after Traumatic Brain Injury Is Independent of Coagulation Factor XI. J Neurotraum. (IF 4,7)

10. Dittmeier M, Wassmuth K, Schuhmann MK, Kraft P, Kleinschnitz C, Fluri F (2016). Dabigatran etexilate reduces thrombin-induced inflammation and thrombus formation in experimental ischemic stroke. Curr Neurovasc Res 13:199-206 (IF 2,1)

11. Krupka J, May F, Weimer T, Pragst I, Kleinschnitz C, Stoll G, Panousis C, Dickneite G, Nolte MW (2016). The Coagulation Factor XIIa Inhibitor rHA-Infestin-4 Improves Outcome after Cerebral Ischemia/Reperfusion Injury in Rats. PloS one 11, e0146783. (IF 3,1)

12. Ruck T, Bittner S, Afzali AM, Göbel K, Glumm S, Kraft P, Sommer C, Kleinschnitz C, Preuße C, Stenzel W, Wiendl H, Meuth SG (2015). The NKG2D-IL-15 signaling pathway contributes to T-cell mediated pathology in inflammatory myopathies Oncotarget 6:43230-40 (IF 5,0)

13. Schuhmann MK, Bittner S, Meuth SG, Kleinschnitz C, Fluri F (2015) Fingolimod (FTY720-P) Does Not Stabilize the Blood-Brain Barrier under Inflammatory Conditions in an in Vitro Model. Int J Mol Sci 16:29454-66 (IF 3,3)

14. Verhenne S, Denorme F, Libbrecht S, Vandenbulcke A, Pareyn I, Deckmyn H, Lambrecht A, Nieswandt B, Kleinschnitz C, Vanhoorelbeke K, De Meyer SF (2015) Platelet-derived VWF is not essential for normal thrombosis and hemostasis but fosters ischemic stroke injury in mice.. Blood 126:1715-22 (IF 11,8)

15. Rovituso D, Duffy C, Schroeter M, Kaiser C, Kleinschnitz C, Bayas A, Elsner A, Kuerten S (2015) The brain antigen-specific B cell response correlates with glatiramer acetate responsiveness in relapsing-remitting multiple sclerosis patients. Sci Rep 5:14265 (IF 5,2)

16. Schleicher RI, Reichenbach F, Kraft P, KumarA, Lescan M, Todt F, Göbel K, Geisler T, Bauer A, Olbrich M, Schaller M, Wesselborg S, O’Reilly L, Meuth SG, Schulze-Osthoff K, Gawaz M, Li X, Kleinschnitz C, Edlich F, Langer HF (2015) Platelets induce apoptosis via membrane-bound FasL. Blood 126:1483-93 (IF 11,8)

17. Warnke C, Stettner M, Lehmensiek V, Dehmel T, Mausberg AK, von Geldern G, Gold R, Kümpfel T, Hohlfeld R, Mäurer M, Stangel M, Straeten V, Limmroth V, Weber T, Kleinschnitz C, Wattjes MP, Svenningsson A, Olsson T, Hartung HP, Hermsen D, Tumani H, Adams O, Kieseier BC (2015) Natalizumab exerts a suppressive effect on surrogates of B cell function in blood and CSF. Mult Scler J 21:1036-44 (IF 4,7)

18. Fluri F, Grünstein D, Cam E, Ungethuem U, Hatz F, Schäfer J, Samnick S, Israel I, Kleinschnitz C, Orts-Gil G, Moch H, Zeis T, Schaeren-Wiemers N, Seeberger P (2015) Fullerenols and glucosamine fullerenes reduce infarct volume and cerebral inflammation after ischemic stroke in normotensive and hypertensive rats. Exp Neurol 265:142-51 (IF 4,7)

19. Cherpokova D, Bender M, Morowski M, Kraft P, Schuhmann MK, Akbar SM, Sultan CS, Hughes CE, Kleinschnitz C, Stoll G, Dragone LL, Watson SP, Tomlinson MG, Nieswandt B (2015) SLAP/SLAP2 prevent excessive platelet (hem)ITAM signaling in thrombosis and ischemic stroke in mice. Blood 125:185-94 (IF 11,8)

20. Luger S, Hohmann C, Kraft P, Gunreben I, Neumann-Haefelin T, Kleinschnitz C, Steinmetz H, Foerch C, Pfeilschifter W (2015) Adherence to oral anticoagulant therapy in secondary stroke prevention – impact of the novel oral anticoagulants. Patient Prefer Adherence, 9:1695-705 (IF 1,7)

21. Sergott RC, Bennett JL, Rieckmann P, Montalban X, Mikol D, Freudensprung U, Plitz T, van Beek J for the ATON Trial Group (2015) J Neurol Sci 351:174-8 (IF 2,1)

22. Warnke C, von Geldern G, Markwerth P, Dehmel T, Hoepner R, Gold R, Pawlita M, Kümpfel T, Mäurer M, Stangel M, Wegner F, Hohlfeld R, Straeten V, Limmroth V, Weber T, Hermsen D, Kleinschnitz C, Hartung HP, Wattjes MP, Svenningson A, Major E, Olsson T, Kieseier BC, Adams O (2014) The CSF JCV antibody index for diagnosis of natalizumab-associated PML. Annals Neurol 76:792-801 (IF 9,9)

23. Gelderblom M, Melzer N, Schattling B, Göb E, Hicking G, Arunachalam P, Bittner S, Ufer F, Herrmann AM, Bernreuther C, Glatzel M, Gerloff C, Kleinschnitz C, Meuth SG, Friese MA, Magnus T (2014) TRPM2 cation channel regulates detrimental immune cell invasion in ischemic stroke. Stroke 45:3395-402 (IF 5,8)

24. Kleikers PW, Dao VT, Göb E, Hooijmans C, Debets J, van Essen H, Kleinschnitz C, Schmidt HH (2014) SFRR-E Young Investigator AwardeeNOXing out stroke: Identification of NOX4 and 5as targets in blood-brain-barrier stabilisation and neuroprotection. Free Radic Biol Med 75 Suppl 1:S16 (IF 5,8)

25. Hohmann C, Milles B, Schinke M, Schroeter M, Ulzheimer J, Kraft P, Kleinschnitz C, Lehmann PV, Kuerten S (2014) Categorization of multiple sclerosis relapse subtypes by B cell profiling in the blood. Acta Neuropathol Commun 2:138 (kein IF)

26. Göbel K, Schuhmann MK, Pankratz S, Stegner D, Herrmann AM, Braun A, Breuer J, Bittner S, Ruck T, Wiendl H, Kleinschnitz C, Nieswandt B, Meuth SG (2014) Phospholipase D1 mediates lymphocyte adhesion and migration in a model of autoimmune central nervous system inflammation. Eur J Immunol 44:2295-305 (IF 4,2)

27. Bittner S, Ruck T, Göbel K, Henschel C, Afzali AM, Göb E, Müntefering T, Kleinschnitz C, Wiendl H, Meuth SG (2014) Effects of Glatiramer Acetate in a Spontaneous Model of Autoimmune Neuroinflammation. Am J Pathol, 184:2056-65 (IF 4,2)

28. Rovituso D, Heller S, Schroeter M, Kleinschnitz C, Kuerten S (2014) B1 cells are unaffected by immune modulatory treatment in remitting-relapsing multiple sclerosis patients. J Neuroimmunol 272:86-90 (IF 2,5)

29. Luger S, Hohmann C, Kraft P, Halmer R, Gunreben I, Neumann-Haefelin T, Kleinschnitz C, Walter S, Haripyan V, Steinmetz H, Foerch C, Pfeilschifter W (2014) Prescription frequency and predictors for the use of novel direct oral anticoagulants for secondary stroke prevention in the first year after their marketing in Europe - a multicentric evaluation. Int J Stroke 9:569-75 (IF 5,8)

30. Trebst C, Jarius S, Berthele A, Paul F, Schippling S, Wildemann B, Borisow N, Kleiter I, Aktas O, Kümpfel T; Neuromyelitis Optica Study Group (NEMOS) (2014) Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol 261:1-16 (IF 3,4)

31. Niklass S, Stoyanov S, Garz C, Bueche CZ, Mencl S, Reymann K, Heinze H-J, Kleinschnitz C, Schreiber S (2014) Intravital imaging in spontaneously hypertensive stroke-prone rats – a pilot study. Exp Transl Stroke Med 6:1 (kein IF)

32. Ehling P, Göb E, Bittner S, Budde T, Ludwig A, Kleinschnitz C, Meuth SG (2013) Ischemia-induced cell depolarization: does the hyperpolarization-activated cation channel HCN2 affect the outcome after stroke in mice? Exp Transl Stroke Med 5:16 (kein IF)

33. Ringelstein M, Metz I, Ruprecht K, Koch A, Rappold J, Ingwersen J, Mathys C, Jarius S, Brück W, Hartung HP, Paul F, Aktas O; for the Neuromyelitis Optica Study Group (NEMOS) (2013) Contribution of spinal cord biopsy to diagnosis of aquaporin-4 antibody positive neuromyelitis optica spectrum disorder. Mult Scler J 20:882-888 (IF 4,7)

34. Bittner S, Ruck T, Schuhmann MK, Herrmann AM, Ou Maati HM, Bobak N, Göbel K, Langhauser F, Stegner D, Ehling P, Borsotto M, Pape HC, Nieswandt B, Kleinschnitz C, Heurteaux C, Galla HJ, Budde T, Wiendl H, Meuth SG (2013) Endothelial TWIK-related potassium channel-1 is a critical regulator of immune cell trafficking into the CNS. Nat Med 19:1161-5 (IF 30,4)

35. Deppermann C, Cherpokova D, Nurden P, Schulz JN, Thielmann I, Kraft P, Vögtle T, Kleinschnitz C, Dütting S, Krohne G, Eming SA, Nurden AT, Eckes B, Stoll G, Stegner D, Nieswandt B (2013) Gray platelet syndrome and defective thrombo-inflammation in Nbeal2-deficient mice. J Clin Invest pii: 69210 (IF 12,6)

36. Schwab N, Schneider-Hohendorf T, Posevitz V, Breuer J, Göbel K, Windhagen S, Brochet B, Vermersch P, Lebrun-Frenay C, Posevitz-Fejfár A, Capra R, Imberti L, Straeten V, Haas J, Wildemann B, Havla J, Kümpfel T, Meinl I, Niessen K, Goelz S, Kleinschnitz C, Warnke C, Buck D, Gold R, Kieseier BC, Meuth SG, Foley J, Chan A, Brassat D, Wiendl H (2013) L-selectin is a possible biomarker for individual PML risk in natalizumab- treated MS patients. Neurology 81:865-71 (IF 8,7)

37. Harrer A, Tumani H, Niendorf S, Lauda F, Geis C, Weishaupt A, Kleinschnitz C, Rauer S, Kuhle J, Stangel M, Weber F, Uhr M, Linnebank M, Wildemann B, Jarius S, Guger M, Ayzenberg I, Chan A, Zettl U, Wiendl H, Pilz G, Hitzl W, Weber J, Kraus J (2013) Cerebrospinal fluid parameters of B cell-related activity in patients with active disease during natalizumab therapy. Mult Scler J 19:1209-12 (IF 4,7)

38. Thielmann I, Stegner D, Kraft P, Hagedorn I, Krohne G, Kleinschnitz C, Stoll G, Nieswandt B (2012) Redundant functions of phospholipases D1 and D2 in platelet α-granule release. J Thromb Haemost 10:2361-72 (IF 5,6)

39. Göbel K, Wedell JH, Herrmann AM, Wachsmuth L, Pankratz S, Bittner S, Budde T, Kleinschnitz C, Faber C, Wiendl H, Meuth SG (2013) 4-Aminopyridine ameliorates mobility but not disease course in an animal model of multiple sclerosis. Exp Neurol 248C:62-71 (IF 4,7)

40. Mencl S, Garz C, Niklass S, Braun H, Göb E, Homola G, Heinze HJ, Reymann KG, Kleinschnitz C, Schreiber S (2013) Early microvascular dysfunction in cerebral small vessel disease is not detectable on 3.0 Tesla magnetic resonance imaging: a longitudinal study in spontaneously hypertensive stroke-prone rats. Exp Transl Stroke Med 5:8 (kein IF)

41. Morowski M, Vögtle T, Kraft P, Kleinschnitz C, Stoll G, Nieswandt B (2013) Only severe thrombocytopenia results in bleeding and defective thrombus formation in mice. Blood 121:4938-47 (IF 11,8)

42. Andronic J, Bobak N, Bittner S, Ehling P, Kleinschnitz C, Herrmann AM, Zimmermann H, Sauer M, Wiendl H, Budde T, Meuth SG, Sukhorukov VL (2013) Identification of two-pore domain potassium channels as potent modulators of osmotic volume regulation in human T lymphocytes. Biochim Biophys Acta - Biomembranes 1828:699-707 (IF 3,7)

43. van Kruchten R, Braun A, Feijge MA, Kuijpers MJ, Rivera-Galdos R, Kraft P, Stoll G, Kleinschnitz C, Bevers EM, Nieswandt B, Heemskerk JW (2012) Antithrombotic Potential of Blockers of Store-Operated Calcium Channels in Platelets. Arterioscler Thromb Vasc Biol 32:1717-23 (IF 6,0)

44. Jarius S, Ruprecht K, Wildemann B, Kuempfel T, Ringelstein M, Geis C, Kleiter I, Kleinschnitz C, Berthele A, Brettschneider J, Hellwig K, Hemmer B, Linker RA, Lauda F, Mayer CA, Tumani H, Melms A, Trebst C, Stangel M, Marziniak M, Hoffmann F, Schippling S, Faiss JH, Neuhaus O, Ettrich B, Zentner C, Guthke K, Hofstadt-van Oy U, Reuss R, Pellkofer H, Ziemann U, Kern P, Wandinger KP, Then Bergh F, Boettcher T, Langel S, Liebetrau M, Rommer PS, Niehaus S, Munch C, Winkelmann A, Zettl UK, Metz I, Veauthier C, Sieb JP, Wilke C, Hartung HP, Aktas O, Paul F (2012) Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients. J Neuroinflamm 9:14 (IF 4,7)

45. Kleiter I, Hellwig K, Berthele A, Kümpfel T, Linker RA, Hartung HP, Paul F, Aktas O; Neuromyelitis Optica Study Group (2012) Failure of natalizumab to prevent relapses in neuromyelitis optica. Arch Neurol 69:239-45 (IF 7,4)

46. Weise G, Basse-Lüsebrink TC, Kleinschnitz C, Kampf T, Jakob PM, Stoll G (2011) In vivo imaging of stepwise vessel occlusion in cerebral photothrombosis of mice by 19F MRI. PLoS One 6:e28143 (IF 3,1)

47. Pleines I, Hagedorn I, Gupta S, May F, Chakarova L, van Hengel J, Offermanns S, Krohne G, Kleinschnitz C, Brakebusch C, Nieswandt B (2011) Megakaryocyte-specific RhoA deficiency causes macrothrombocytopenia and defective platelet activation in hemostasis and thrombosis. Blood 119:1054-63 (IF 11,8)

48. Bittner S, Bobak N, Feuchtenberger M, Herrmann AM, Göbel K, Kinne RW, Hansen AJ, Budde T, Kleinschnitz C, Frey O, Tony HP, Wiendl H, Meuth SG (2011) Expression of K2P5.1 potassium channels on CD4+ T lymphocytes correlates with disease activity in rheumatoid arthritis patients. Arthritis Res Ther 13:R21 (IF 4,0)

49. Herrmann A, Göbel K, Simon OJ, Melzer N, Schuhmann MK, Stenner MP, Weishaupt A, Kleinschnitz C, Bittner S, Meuth P, Stuve O, Budde T, Kieseier BC, Wiendl H, Meuth SG (2010) Glatiramer acetate attenuates proinflammatory T cell responses but does not directly protect neurons from inflammatory cell death. Am J Pathol 177:3051-60 (IF 4,2)

50. Hagedorn I, Schmidbauer S, Pleines I, Kleinschnitz C, Kronthaler U, Stoll G, Dickneite G, Nieswandt B (2010) Factor XIIa inhibitor recombinant human albumin Infestin-4 abolishes occlusive arterial thrombus formation without affecting bleeding. Circulation 121:1510-7 (IF 17,1)

51. Elvers M, Stegner D, Hagedorn I, Kleinschnitz C, Braun A, Kuijpers ME, Boesl M, Chen Q, Heemskerk JW, Stoll G, Frohman MA, Nieswandt B (2010) Impaired alpha(IIb)beta(3) integrin activation and shear-dependent thrombus formation in mice lacking phospholipase D1. Sci Signal 3:ra1 (IF 7,4)

52. Schuhmann MK, Stegner D, Berna-Erro A, Bittner S, Braun A, Kleinschnitz C, Stoll G, Wiendl H, Meuth SG, Nieswandt B (2010) Stromal interaction molecules 1 and 2 are key regulators of autoreactive T cell activation in murine autoimmune central nervous system inflammation. J Immunol 184:1536-42 (IF 5,0)

53. Ehling P, Bittner S, Bobak N, Schwarz T, Wiendl H, Budde T, Kleinschnitz C, Meuth SG (2010) Two pore domain potassium channels in cerebral ischemia: a focus on K2P9.1 (TASK3, KCNK9). Exp Transl Stroke Med 2:14 (kein IF)

54. Radue EW, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Rudick RA, Lublin FD, Weinstock-Guttman B, Wynn DR, Fisher E, Papadopoulou A, Lynn F, Panzara MA, Sandrock AW; SENTINEL Investigators (2010) Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis. J Neurol Sci 292:28-35 (IF 2,1)

55. Braeuninger S, Kleinschnitz C, Stoll G (2010) Interleukin-18 does not influence infarct volume or functional outcome in the early stage after transient focal brain ischemia in mice. Exp Transl Stroke Med 2:1 (kein IF)

56. Pham M, Helluy X, Braeuninger S, Jakob P, Stoll G, Kleinschnitz C, Bendszus M (2010) Outcome of experimental stroke in C57Bl/6 and Sv/129 mice assessed by multimodal ultra-high field MRI. Exp Transl Stroke Med 2:6 (kein IF)

57. Berna-Erro A, Braun A, Kraft R, Kleinschnitz C, Schuhmann MK, Stegner D, Wultsch T, Eilers J, Meuth SG, Stoll G, Nieswandt B (2009) STIM2 regulates capacitive Ca2+ entry in neurons and plays a key role in hypoxic neuronal cell death. Sci Signal 2:ra67 (IF 7,4)

58. Braun A, Varga-Szabo D, Kleinschnitz C, Pleines I, Bender M, Austinat M, Bosl M, Stoll G, Nieswandt B (2009) Orai1 (CRACM1) is the platelet SOC channel and essential for pathological thrombus formation. Blood 113:2056-63 (IF 11,8)

59. Varga-Szabo D, Braun A, Kleinschnitz C, Bender M, Pleines I, Pham M, Renné T, Stoll G, Nieswandt B (2008) The calcium sensor STIM1 is an essential mediator of arterial thrombosis and ischemic brain infarction. J Exp Med 205:1583- 91 (IF 11,2)

60. Ip CW, Kohl B, Kleinschnitz C, Reuss B, Nave KA, Kroner A, Martini R (2008) Origin of CD11b+ macrophage-like cells in the CNS of PLP-overexpressing mice: Low influx of haematogenous macrophages and unchanged blood-brain-barrier in the optic nerve. Mol Cell Neurosci 38:489-94 (IF 3,6)

61. Fischer S, Kleinschnitz C, Müller M, Kobsar I, Rollins BJ, Weishaupt A, Troppmair J, Martini R (2008) Monocyte chemoattractant protein-1 (MCP-1; CCL2) is an early macrophage activator in peripheral nerves of mice heterozygously deficient in P0. Mol Cell Neurosci 37:359-66 (IF 3,6)

62. Siglienti I, Chan A, Kleinschnitz C, Jander S, Toyka KV, Gold R, Stoll G (2007) Downregulation of transforming growth factor-beta2 facilitates inflammation in the central nervous system by reciprocal astrocyte/microglia interactions. J Neuropathol Exp Neurol 66:47-56 (IF 3,4)

63. Meuth SG, Aller IM, Munsch T, Schuhmacher T, Seidenbecher T, Meuth P, Kleinschnitz C, Pape HC, Wiendl H, Wisden W, Budde T (2006) The contribution of TASK-1-containing channels to the function of dorsal lateral geniculate thalamocortical relay neurons. Mol Pharmacol 69:1468-76 (IF 3,9)

64. Rodriguez-Palmero M, Franch A, Castell M, Pelegri C, Perez-Cano FJ, Kleinschnitz C, Stoll G, Hunig T, Castellote C (2006) Effective treatment of adjuvant arthritis with a stimulatory CD28-specific monoclonal antibody. J Rheumatol 33:110 (IF 3,2)

65. Siglienti I, Bendszus M, Kleinschnitz C, Stoll G (2005) Cytokine profile of iron-laden macrophages: Implications for cellular magnetic resonance imaging. J Neuroimmunol 173:166-73 (IF 2,5)

66. Bendszus M, Wessig C, Schutz A, Horn T, Kleinschnitz C, Sommer C, Misselwitz B, Stoll G (2005) Assessment of nerve degeneration by gadofluorine M-enhanced magnetic resonance imaging. Ann Neurol 57:388-95 (IF 9,9)

67. George A, Kleinschnitz C, Zelenka M, Brinkhoff J, Stoll G, Sommer C (2004) Wallerian degeneration after crush or chronic constriction injury of rodent sciatic nerve is associated with a depletion of endoneurial interleukin-10 protein. Exp Neurol 188:187-91 (IF 4,7)

68. Kroner A, Maurer M, Loserth S, Kleinschnitz C, Hemmer B, Rosche B, Toyka KV, Rieckmann P (2004) Analysis of the monocyte chemoattractant protein 1 -2518 promoter polymorphism in patients with multiple sclerosis. Tissue Antigens 64:70-3 (IF 2,1)

69. Stoll G, Schroeter M, Jander S, Siebert H, Wollrath A, Kleinschnitz C, Bruck W (2004) Lesion-associated expression of transforming growth factor-beta-2 in the rat nervous system: evidence for down-regulating the phagocytic activity of microglia and macrophages. Brain Pathol 14:51-8 (IF 5,3)

70. Nedvetsky PI, Kleinschnitz C, Schmidt HH (2002) Regional distribution of protein and activity of the nitric oxide receptor, soluble guanylyl cyclase, in rat brain suggests multiple mechanisms of regulation. Brain Res 20:148-54 (IF 2,6)

71. Zabel U, Kleinschnitz C, Oh P, Nedvetsky PI, Smolenski A, Müller H, Kronich P, Kugler P, Walter U, Schnitzer JE, Schmidt HHW (2002) Calcium-dependent membrane association sensitises soluble guanylyl cyclase to NO. Nat Cell Biol 4:307-11 (IF 18,7)

2. Übersichtsarbeiten
a. Erst-/Seniorautor

1. Liesz, A, Kleinschnitz, C (2016). Regulatory T Cells in Post-stroke Immune Homeostasis. Transl stroke Res 7: 313-321 (IF 4,5)

2. Diener, HC, Kleinschnitz, C (2016). Non-Vitamin K Oral Anticoagulants in Stroke Patients: Practical Issues. Journal of Stroke 18:138-145(IF 4,8)

3. De Meyer SF, Denorme F, Langhauser F, Göb E, Fluri F, Kleinschnitz C (2016) Thrombo-inflammation in Stroke Brain Damage. Stroke, 47:1165-72 (IF 5,8)

4. Hopp, S, Albert-Weissenberger, C, Mencl, S, Bieber, M, Schuhmann, MK, Stetter, C, Nieswandt, B, Schmidt, PM, Monoranu, CM, Alafuzoff, I, Marklund, N, Nolte, MW, Siren, AL, Kleinschnitz, C (2016). Targeting coagulation factor XII as a novel therapeutic option in brain trauma. Ann Neurol 79: 970-982 (IF 9,9)

5. Fluri F, Schuhmann MK, Kleinschnitz C (2015) Animal models of ischemic stroke and their application in clinical research. Drug Des Develop Ther 9:3445-54 (IF 2,9)

6. Kleinschnitz C, Linker RA, Magnus T, Korn T (2015) Report on the 6th scientific meeting of the “Verein zur Förderung des Wissenschaftlichen Nachwuchses in der Neurologie” (NEUROWIND e.V.) held in Motzen, Germany, Oct. 31th – Nov. 2nd, 2014. Exp Transl Stroke Med 7:1 (kein IF)

7. Albert-Weissenberger C, Mencl S, Hopp S, Kleinschnitz C*, Sirén AL* (2014) Role of the kallikrein-kinin system in traumatic brain injury. Front Cell Neurosci 8:345 (*gemeinsamer Seniorautor) (IF 4,6)

8. Schmidt A, Minnerup J, Kleinschnitz C (2013) Emerging neuroprotective drugs for the treatment of acute ischemic stroke. Expert Opin Emerg Drugs 18:109-20 (IF 2,1)

9. Albert-Weißenberger C, Sirén AL, Kleinschnitz C (2013) Ischemic stroke and traumatic brain injury: The role of the kallikrein-kinin system. Prog Neurobiol 101-102:65-82 (IF 13,2)

10. Minnerup J, Sutherland BA, Buchan AM, Kleinschnitz C (2012) Neuroprotection for stroke: Current status and future perspectives. Int J Mol Sci, 13:11753-72 (IF 3,3)

11. Kleinschnitz C, Plesnila N (2012) Experimentelle Therapieansätze des ischämischen Schlaganfalls [Experimental therapies for ischemic stroke]. Nervenarzt 83:1275-81 (IF 0,8)

12. Kraft P, De Meyer SF, Kleinschnitz C (2012) Next-generation antithrombotics in Ischemic stroke: preclinical perspective on 'bleeding-free antithrombosis'. J Cereb Blood Flow Metab 32:1831-40 (IF 4,9)

13. Magnus T, Wiendl H, Kleinschnitz C (2012) Immune mechanisms of stroke. Curr Opin Neurol 25:334-40 (IF 4,5)

14. Kleinschnitz C, Meuth SG, Magnus T, Korn T, Linker RA (2012) Report on the 3‘rd scientific meeting of the „Verein zur Förderung des Wissenschaftlichen Nachwuchses in der Neurologie“ (NEUROWIND e.V.) held in Motzen, Germany, Nov. 4’th – Nov. 6’th, 2011. Exp Transl Stroke Med 4:2 (kein IF)

15. Sutherland BA, Minnerup J, Balami JS, Arba F, Buchan AM, Kleinschnitz C (2012) Neuroprotection for ischaemic stroke: translation from the bench to the bedside. Int J Stroke 7:407-18 (IF 3,0)

16. De Meyer S, Stoll G, Wagner DD, Kleinschnitz C (2012) von Willebrand factor: an emerging target in stroke therapy. Stroke 43:599-606 (IF 5,8)

17. Pham M, Stoll G, Nieswandt B, Bendszus M, Kleinschnitz C (2011) Blood coagulation factor XII – a neglected player in stroke pathophysiology. J Mol Med 90:119-26 (IF 4,9)

18. Kraft P, Nieswandt B, Stoll G, Kleinschnitz C (2011) [Acute ischemic stroke : New approaches to antithrombotic treatment.]. Nervenarzt 83:435-49 (IF 0,8)

19. Meuth SG, Kleinschnitz C (2010) Multifocal motor neuropathy: update on clinical characteristics, pathophysiological concepts and therapeutic options. Eur Neurol 63:193-204 (IF 1,4)

20. Braeuninger S, Kleinschnitz C (2009) Rodent models of focal cerebral ischemia: procedural pitfalls and translational problems. Exp Transl Stroke Med 1:8 (kein IF)

21. Kleinschnitz C, Meuth SG, Wiendl H (2008) The Trials and Errors in MS Therapy. Int MS J 15:79-90 (kein IF)

22. Kleinschnitz C, Meuth SG, Stuve O, Kieseier B, Wiendl H (2007) Multiple Sclerosis Therapy: An Update on Recently Finished Trials. J Neurol 254:1473-90 (IF 3,4)

23. Kleinschnitz C, Meuth SG, Kieseier B, Wiendl H (2007) Immunotherapeutic Approaches in MS: Update on Pathophysiology and Emerging Agents or Strategies 2006. Endocr Metab Immune Dis - Drug Targets 7:35-63 (IF 2,0)

24. Kleinschnitz C, Meuth SG, Kieseier B, Wiendl H (2007) Multiple Sklerose-Update zur Pathophysiologie und neuen Immuntherapeutischen Ansätzen. Nervenarzt 78:883-911 (IF 0,8)

25. Kleinschnitz C, Reiners KH (2006) Multifokale Motorische Neuropathie: Klinische Merkmale, Pathophysiologie und Therapie. Klin Neurophysiol 37:169-79 (IF 0,2)

b. Co-Autor

1. Pfeuffer, S, Ruck, T, Kleinschnitz, C, Wiendl, H, Meuth, SG (2016). Failed, interrupted and inconclusive trials on relapsing multiple sclerosis treatment: update 2010-2015. Expert rev neurother 16:689-700 (IF 2,6)

2. Kleiter I, Gahlen A, Borisow N, Fischer K, Wernecke KD, Wegner B, Hellwig K, Pache F, Ruprecht K, Havla J, Krumbholz M, Kumpfel T, Aktas O, Hartung HP, Ringelstein M, Geis C, Kleinschnitz C, Berthele A, Hemmer B, Angstwurm K, Stellmann JP, Schuster S, Stangel M, Lauda F, Tumani H, Mayer C, Zeltner L, Ziemann U, Linker R, Schwab M, Marziniak M, Then Bergh F, Hofstadt-van Oy U, Neuhaus O, Winkelmann A, Marouf W, Faiss J, Wildemann B, Paul F, Jarius S, Trebst C, Neuromyelitis Optica Study Group. (2016). Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses. Ann Neurol 79: 206-216. (IF 9,9)

3. Purrucker JC, Haas K, Rizos T, Khan S, Wolf M, Hennerici MG, Poli S, Kleinschnitz C, Steiner T, Heuschmann PU, Veltkamp R (2016). Early Clinical and Radiological Course, Management, and Outcome of Intracerebral Hemorrhage Related to New Oral Anticoagulants. JAMA neurology 73: 169-177 (IF 8,2)

4. Linker RA, Kallmann BA, Kleinschnitz C, Rieckmann P, Mäurer M, Schwab S (2015) „Time is brain“ bei der schubförmigen Multiplen Sklerose: Aktuelle Behandlungskonzepte in der Immuntherapie. Nervenarzt, 86:1528-37 (IF 0,8)

5. Gelderblom M, Sobey CG, Kleinschnitz C, Magnus T (2015) Danger signals in stroke. Ageing Res Rev 24:77-82 (IF 7,5)

6. Mezger M, Goebel K, Kraft P, Meuth SG, Kleinschnitz C, Langer HF (2015) Platelets and vascular inflammation of the brain. Hämostaseologie 35:244-51 (IF 1,6)

7. Liesz A, Hu X, Kleinschnitz C, Offner H (2015) Functional Role of Regulatory Lymphocytes in Stroke: Facts and Controversies. Stroke 46:1422-30 (IF 5,8)

8. Linker RA, Magnus T, Korn T, Kleinschnitz C, Meuth SG (2014) Report on the 5'th scientific meeting of the "Verein zur Förderung des Wissenschaftlichen Nachwuchses in der Neurologie" (NEUROWIND e.V.) held in Motzen, Germany, Oct. 25th - Oct. 27th, 2013. Exp Transl Stroke Med 5:15 (kein IF)

9. Radermacher KA, Wingler K, Langhauser F, Altenhöfer S, Kleikers P, Hermans R, Hrabě de Angelis M, Kleinschnitz C, Schmidt HH (2013) Neuroprotection after stroke by targeting NOX4 as a source of oxidative stress. Antioxid Redox Signal 2013 18:1418-27 (IF 7,1)

10. Raslan F, Albert-Weißenberger C, Westermaier T, Saker S, Kleinschnitz C, Lee JY (2012) A modified double injection model of cisterna magna for the study of delayed cerebral vasospasm following subarachnoid hemorrhage in rats. Exp Transl Stroke Med. 4:23 (kein IF)

11. Boltze J, Kleinschnitz C, Reymann KG, Reiser G, Wagner DC, Kranz A, Michalski D; the meeting contributors (2012) Neurovascular pathophysiology in cerebral ischemia, dementia and the ageing brain - current trends in basic, translational and clinical research. Exp Transl Stroke Med. 4:14 (kein IF)

12. Raslan F, Albert-Weiszenberger C, Ernestus RI, Kleinschnitz C, Siren AL (2012) Focal brain trauma in the cryogenic lesion model in mice. Exp Transl Stroke Med 4:6 (kein IF)

13. Albert-Weißenberger C, Várrallyay C, Raslan F, Kleinschnitz C, Sirén AL (2012) An experimental protocol for mimicking pathomechanisms of traumatic brain injury in mice. Exp Transl Stroke Med 4:1 (kein IF)

14. Radermacher KA, Wingler K, Kleikers PW, Altenhöfer SA, Hermans JJR, Kleinschnitz C, Schmidt HHHW (2012) The 1027th target candidate in stroke: Will NADPH oxidase hold up? Exp Transl Stroke Med 4:11 (kein IF)

15. Braeuninger S, Kleinschnitz C, Nieswandt B, Stoll G (2012) Focal cerebral ischemia. Methods Mol Biol 788:29-42 (kein IF)

16. Nieswandt B, Kleinschnitz C, Stoll G (2011) Ischaemic stroke: a thrombo-inflammatory disease? J Physiol – London 589:4115-23 (IF 4,7)

17. Bittner S, Höhn K, Göbel K, Kleinschnitz C, Wiendl H, Meuth SG (2011) [Pregabalin and gabapentin in multiple sclerosis: Clinical experiences and therapeutic implications.] Nervenarzt 82:1273-80 (IF 0,8)

18. Magnus T, Linker R, Meuth SG, Kleinschnitz C, Korn T (2011) Report on the 2nd scientific meeting of the "Verein zur Förderung des Wissenschaftlichen Nachwuchses in der Neurologie" (NEUROWIND e.V.) held in Mittenwalde/Motzen, Germany, 29’th – Oct. 31’st, 2010. Exp Transl Stroke Med 3:3 (kein IF)

19. Stoll G, Kleinschnitz C, Nieswandt B (2010) Combating innate inflammation: a new paradigm for acute treatment of stroke? Annals New York Acad Sci, 1207:149-54 (IF 4,5)

20. Meuth SG, Bittner S, Ulzheimer JC, Kleinschnitz C, Kieseier BC, Wiendl H (2010) Therapeutic Approaches to Multiple Sclerosis: An update on failed and interrupted treatment trials or trials of unknown significance – A focus on neuroprotective and alternative treatment strategies. Biodrugs, 24:317-30 (IF 2,9)

21. Ulzheimer JC, Meuth SG, Bittner S, Kleinschnitz C, Kieseier BC, Wiendl H (2010) Therapeutic Approaches to Multiple Sclerosis: An update on failed and interrupted treatment trials. Biodrugs 24:249-74 (IF 2,9)

22. Stoll G, Kleinschnitz C, Nieswandt B (2010) The role of glycoprotein Ibalpha and von Willebrand factor interaction in stroke development. Hamostaseologie 30:136-8 (IF 1,6)

23. Bueter W, Saunders NR, Mallard C, Bauer HC, Stolp HB, Kavelaars A, Dammann O; NEUROBID consortium (2010) NEUROBID-an EU-funded project to study the developing brain barriers. Int J Dev Neurosci 28:411-2 (IF 2,4)

24. Magnus T, Linker R, Meuth SG, Kleinschnitz C, Korn T (2010) Report on the 1st scientific meeting of the "Verein zur Förderung des Wissenschaftlichen Nachwuchses in der Neurologie" (NEUROWIND e.V.) held in Mittenwalde/Motzen, Germany, Oct. 30th - Nov. 1st, 2009. Exp Transl Stroke Med 2:7 (kein IF)

25. Meuth SG, Melzer N, Kleinschnitz C, Budde T, Wiendl H (2009) Multiple Sklerose – eine Kanalopathie? [Multiple sclerosis - a channelopathy? Targeting ion channels and transporters in inflammatoryy neurodegeneration.] Nervenarzt 80:422-9 (IF 0,8)

26. Meuth SG, Kleinschnitz C, Wiendl H (2009) Recent clinical trials and future therapies. J Neurol 255:Suppl 6 93-6 (IF 3,4)

27. Stoll G, Kleinschnitz C, Nieswandt B (2008) Molecular mechanisms of thrombus formation in ischemic stroke: Novel insights and targets for treatment. Blood 112:3555-62 (IF 11,8)

28. Multiple Sclerosis Therapy Consensus Group (MSTCG), Wiendl H, Toyka KV, Rieckmann P, Gold R, Hartung HP, Hohlfeld R (2008) Basic and escalating immunomodulatory treatments in multiple sclerosis: Current therapeutic recommendations. J Neurol 255:1449-63 (IF 3,4)

29. Multiple Sklerose Therapie Konsensus Gruppe (MSTKG) (2006) Escalating immunomodulatory therapy of multiple sclerosis: Update (September 2006). Nervenarzt 77:1506-18 (IF 0,8)

3. Fallberichte
a. Erst-/Seniorautor
1. Fluri F, Fleischer M, Kleinschnitz C (2015) Accidental Thrombolysis in a Stroke Patient Receiving Apixaban. Cerebrovasc Dis Extra 5:55-6 (kein IF)

2. Fluri F, Heinen F, Kleinschnitz C (2013) Intravenous thrombolysis in a stroke patient receiving rivaroxaban. Cerebrovasc Dis Extra 3:153-5. (kein IF)

3. Geis C, Gunreben I, Kleinschnitz C (2013) Acute tetraparesis secondary to bilateral precentral gyral cerebral ischemia: a case report. J Med Case Rep 7:61 (kein IF)

4. Golombeck SK, Wessig C, Monoranu CM, Schütz A, Solymosi L, Melzer N, Kleinschnitz C (2012) Fatal atypical reversible posterior leukoencephalopathy syndrome: a case report. J Med Case Rep 7:14 (kein IF)

5. Hansen N, Beck M, Leykamm S, Kleinschnitz C (2009). Arm und Blutzucker außer Kontrolle. MMW Fortschr Med 151:41-2 (kein IF)

6. Kleinschnitz C, Bittner S, Meuth S (2009) Langzeitverlauf unter Interferonβ-1b bei kardialer Komorbidität. Aktuelle Neurologie S3:S231 (IF 0,3)

7. Meuth S, Bittner S, Kleinschnitz C (2009) Präklinische Multiple Sklerose und Therapieoptionen. Aktuelle Neurologie S3:S268 (IF 0,3)

b. Co-Autor
1. Meuth SG, Kleinschnitz C, Frank M, Wessig C, Bendszus M, Kress W, Wiendl H (2006) Why a positive genetic test for myotonic dystrophy type I does not always imply the right diagnosis. J Neurol Neurosurg Psychiatry 77:1381-82 (IF 6,4)

2. Frank M, Meuth SG, Wessig C, Kleinschnitz C, Rieckmann P (2007) Schmerzhafte progrediente Paraparese mit sklerodermieartigen Hautveränderungen. MMW Fortschr Med 149: 25-7 (kein IF)

4. Buchbeiträge
a. Erst-/Seniorautor
1. Minnerup J, Schmidt A, Albert-Weissenberger C, Kleinschnitz C (2013) Stroke: Pathophysiology and Therapy, Granger JP (Herausgeber), Morgan & Clayton Life Sciences, San Rafael

2. Kleinschnitz C (2012) The kallikrein-kinin system in ischemic stroke and brain trauma. In: The kallikrein-kinin system, Bader M (Herausgeber), Walter de Gruyter, Berlin/Boston

3. Kroner-Milsch A, Kleinschnitz C (2012) Ätiologie und Immunpathogenese der Multiplen Sklerose. In: Autoimmunerkrankungen. Diagnostik und Therapie, Stangel M, Mäurer M (Herausgeber), Springer, Berlin Heidelberg

4. Kleinschnitz C, Stoll G (2008) Inflammation and the role of immune mediators in the pathophysiology of ischemic stroke. In: Inflammation research perspectives, Romano GT (editor), Nova Science Publishers, Inc., New York

b. Co-Autor
1. Braeuninger S, Kleinschnitz C, Stoll G, Nieswandt B (2010) Focal cerebral ischemia. In: Gibbins M, Mahaut-Smith MP (editors), Platelets and Megakaryocytes, Volume 3. Springer, New York, 788:29-42

2. Wiendl H, Melzer N, Kleinschnitz C, Meuth SG (2009) Lessons from the past and future: Approaches for immunological therapies in multiple sclerosis. In: Lucchinetti C, Hohlfeld R (editors.) Blue Books of Practical Neurology. Saunders Elsevier, Philadelphia

5. Leserbriefe/Editorials
a. Erst-/Seniorautor
1. Liesz A, Kleinschnitz C (2015) Mechanisms of neuroinflammation and inflammatory neurodegeneration in acute brain injury. Front Cell Neurosci 5;9:300 (IF 4,2)

2. Kleinschnitz C*, Langhauser F, Wiendl H (2014) Response to Letter Regarding Article, “Blocking of alpha4 Integrin Does Not Protect From Acute Ischemic Stroke in Mice”. Stroke 45:1799-806. (*korrespondierender Autor) (IF 5,8)

3. Kleinschnitz C*, Wiendl H (2013) Con: Regulatory T cells are protective in ischemic stroke. Stroke, 44:e87-8 (*korrespondierender Autor) (IF 5,8)

4. Minnerup J, Kleinschnitz C (2013) No risk, no benefit! Still true for antithrombotic
stroke treatments? Fut Med Chem 5:377-9 (IF 3,7)

5. Minnerup J, Kleinschnitz C (2011) Visualization of clot composition in ischemic stroke: Do we get what we see? Stroke 42:1193-4 (IF 5,8)

6. De Meyer SF, Stoll G, Kleinschnitz C (2010) The pathophysiological relevance of VWF in human and experimental stroke. Stroke, 42:e41 (IF 5,8)

7. Schäbitz WR, Kleinschnitz C (2009) Time to overcome the translational roadblock: Introducing a new open access stroke journal. Exp Transl Stroke Med 1:1 (kein IF)

8. Kleinschnitz C, Austinat M, Bader M, Renné T, Stoll G (2008) Deficiency of Bradykinin Receptor B2 Is Not Detrimental in Experimental Stroke. Hypertension 51:e41 (IF 6,4)

b. Co-Autor
1. Wingler K, Altenhoefer SA, Kleikers PW, Radermacher KA, Kleinschnitz C, Schmidt HH (2012) VAS2870 is a pan-NADPH oxidase inhibitor. Cell Mol Life Sci, 69:3159-60 (IF 5,8)

2. Schmidt HHHW, Wingler K, Kleinschnitz C, Dusting G (2012) NOX4 is a Janus-faced Reactive Oxygen Species Generating NADPH Oxidase. Circ Res, 111:e15-6 (IF 11,0)

3. Bendszus M, Kleinschnitz C, Stoll G (2007) Iron-enhanced MRI in Ischemic Stroke: intravascular trapping vs. inflammation. Stroke 38:e12 (IF 5,8)